A new study demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.
Study shows liraglutide results in increased insulin sensitivity independent of weight loss
- Post author:
- Post published:January 5, 2024
- Post category:uncategorized